ReviewMelanoma management2020
Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?
Review in Melanoma management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Pre-screening value of serum albumin and the glucose-lymphocyte ratio as the "transport-activation" effectors of immune checkpoint inhibitors in small cell lung cancer.Translational lung cancer research · 2025Article
- CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.Nature medicine · 2025Article
- Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial.Molecular oncology · 2025Article
- The neutrophil-to-lymphocyte ratio and the prevalence of cutaneous melanoma: a retrospective observational study of NHANES statistics spanning 1999 to 2018.Archives of dermatological research · 2025Observational
- Pair-matched analysis of Circulating Melanoma Cells (CMCs) before and after Immunotherapy in Relation to other Melanoma-Specific Biomarkers.Journal of Cancer · 2025Article
- The causal relationships of granulocytes and melanoma skin cancer: A univariable and multivariable Mendelian randomization study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Susceptibility of Melanoma Cells to Targeted Therapy Correlates with Protection by Blood Neutrophils.Cancers · 2024Article
- Prognostic Value of the Neutrophil-to-lymphocyte Ratio, Platelet-to- lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Melanoma Patients: A Cohort Study.Acta dermato-venereologica · 2024Article
- Review
- Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma.OncoTargets and therapy · 2024Article
- The role of preoperative hematological inflammatory markers as a predictor of meningioma grade: A systematic review and meta-analysis.Surgical neurology international · 2024Review
- Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.Pigment cell & melanoma research · 2023Article
- TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs.Cell reports. Medicine · 2023Article
- Prognostic Values of Systemic Inflammatory Immunological Markers in Glioblastoma: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Article
- Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma-Persistent Updating.Journal of personalized medicine · 2022Review
- Article
- Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients.Biomedicines · 2022Article
- Prognostic role of an inflammation scoring system in radical resection of oral squamous cell carcinoma.BMC oral health · 2022Article
- Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy.Oncogenesis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neutrophil-to-lymphocyte ratio (NLR) is gaining traction as a biomarker with utility in a variety of malignancies including melanoma. Intact lymphocyte function is necessary for tumor surveillance and destruction, and neutrophils play a role in suppressing lymphocyte proliferation and in the induction of lymphocyte apoptosis. Early research in melanoma indicates that in high-risk localized melanoma, a high NLR is correlated with worse overall and disease-free survival. Similarly, in metastatic melanoma treated with both metastasectomy and immunotherapies, an elevated NLR is predictive of shortened overall survival and progression-free survival. Future studies incorporating NLR into more traditional melanoma prognostic markers while employing more granular outcomes, are needed to realize the full potential of NLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.